

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/027418 A2**

(51) International Patent Classification<sup>7</sup>: **G01N 33/48**

(21) International Application Number:  
PCT/EP2003/010404

(22) International Filing Date:  
18 September 2003 (18.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02021228.8 18 September 2002 (18.09.2002) EP

(71) Applicants (*for all designated States except US*):  
G2M CANCER DRUGS AG [DE/DE]; Paul-Ehrlich-  
Strasse 42-44, 60596 Frankfurt am Main (DE).  
FORSCHUNGSZENTRUM KARLSRUHE GMBH  
[DE/DE]; Hermann-von-Helmholtz-Platz 1, 76344 Eggen-  
stein-Leopoldshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HEINZEL**,  
Thorsten [DE/DE]; Libellenweg 10, 60529 Frankfurt am  
Main (DE). **KRÄMER**, Oliver, H. [DE/DE]; Koselstrasse  
38, 60318 Frankfurt am Main (DE). **GÖTTLICHER**,  
Martin [DE/DE]; Marcesstrasse 1, 80638 München  
(DE). **ZHU**, Ping [CN/DE]; H.-Hesse-Strasse 13, 76351  
Linkenheim (DE). **GOLEBIEWSKI**, Martin [DE/DE];  
Bernhardstrasse 9, 76131 Karlsruhe (DE). **PELICCI**,  
Pier, Giuseppe [IT/IT]; Via Emilia 10, I-20090 Opera

(Milan) (IT). **MAURER**, Alexander, B. [DE/DE]; Rain-  
weg 3, 61352 Bad Homburg (DE). **HENTSCH**, Bernd  
[DE/DE]; Gervinusstrasse 8, 60322 Frankfurt am Main  
(DE). **MINUCCI**, Saverio [IT/IT]; Via Don Minzoni 1,  
I-20090 Opera (Milan) (IT).

(74) Agents: **KELLER**, Günter et al.; **LEDERER** &  
**KELLER**, Prinzregentenstrasse 16, 80538 München (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: THE USE OF MOLECULAR MARKERS FOR THE PRECLINICAL AND CLINICAL PROFILING OF INHIBITORS  
OF ENZYMES HAVING HISTONE DEACETYLASE ACTIVITY

(57) Abstract: The present invention relates to the use of molecular markers and related signaling mechanisms for the preclinical  
and clinical profiling of inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of such  
markers as diagnostic and/or prognostic tools for the treatment of tumor patients with such inhibitors.

WO 2004/027418 A2

G2M Cancer Drugs AG  
Paul-Ehrlich-Straße 42-44  
D-60596 Frankfurt am Main

and

Forschungszentrum Karlsruhe GmbH  
Hermann-von-Helmholtz-Platz 1  
D-76344 Eggenstein-Leopoldshafen

---

**The use of molecular markers for the preclinical and clinical profiling  
of inhibitors of enzymes having histone deacetylase activity**

---

The present invention relates to the use of molecular markers and related signaling mechanisms for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of such markers as diagnostic and/or prognostic tools for the treatment of tumor patients with such inhibitors.

Local remodeling of chromatin is a key step in the transcriptional activation of genes. Dynamic changes in the nucleosomal packaging of DNA must occur to allow transcriptional proteins to contact with the DNA template. One of the most important mechanisms influencing chromatin remodeling and gene transcription are the posttranslational modification of histones and other cellular proteins by acetylation and subsequent changes in chromatin structure (Davie, 1998, Curr Opin Genet Dev 8, 173-8; Kouzarides, 1999, Curr Opin Genet Dev 9, 40-8; Strahl and Allis, 2000, Nature 403, 41-4). In the case of histone hyperacetylation, changes in electrostatic attraction for DNA and

steric hindrance introduced by the hydrophobic acetyl group leads to destabilisation of the interaction of histones with DNA. As a result, acetylation of histones disrupts nucleosomes and allows the DNA to become accessible to the transcriptional machinery. Removal of the acetyl groups allows the histones to bind more tightly to DNA and to adjacent nucleosomes and thus to maintain a transcriptionally repressed chromatin structure. Acetylation is mediated by a series of enzymes with histone acetyltransferase (HAT) activity. Conversely, acetyl groups are removed by specific histone deacetylase (HDAC) enzymes. Disruption of these mechanisms gives rise to transcriptional misregulation and may lead to tumorigenic transformation.

Additionally, other molecules such as transcription factors alter their activity and stability depending on their acetylation status. E.g. PML-RAR, the fusion protein associated with acute promyelocytic leukemia (APL) inhibits p53 through mediating deacetylation and degradation of p53, thus allowing APL blasts to evade p53 dependent cancer surveillance pathways. Expression of PML-RAR in hematopoietic precursors results in repression of p53 mediated transcriptional activation, and protection from p53-dependent apoptosis triggered by genotoxic stresses (X-rays, oxidative stress). However, the function of p53 is reinstalled in the presence of HDAC inhibitors implicating active recruitment of HDAC to p53 by PML-RAR as the mechanism underlying p53 inhibition (Insinga et al. 2002, manuscript submitted). Therefore, factor acetylation plays a crucial role in the anti-tumor activity of HDAC inhibitors.

Nuclear hormone receptors are ligand-dependent transcription factors that control development and homeostasis through both positive and negative control of gene expression. Defects in these regulatory processes underlie the causes of many diseases and play an important role in the development of cancer. Many nuclear receptors, including T3R, RAR and PPAR, can interact with the corepressors N-CoR and SMRT in the absence of ligand and thereby inhibit transcription. Furthermore, N-CoR has also been reported to interact with antagonist-occupied progesterone and estrogen receptors. N-CoR and SMRT have been shown to exist in large protein complexes, which also contain mSin3 proteins and histone deacetylases (Pazin and Kadonaga, 1997; Cell 89, 325-8). Thus, the ligand-induced switch of nuclear receptors from repression to activation reflects the exchange of corepressor and coactivator complexes with antagonistic enzymatic activities.

The N-CoR corepressor complex not only mediates repression by nuclear receptors, but also interacts with additional transcription factors including Mad-1, BCL-6 and ETO. Many of these proteins play key roles in disorders of cell proliferation and differentiation (Pazin and Kadonaga, 1997, *Cell* 89, 325-8; Huynh and Bardwell, 1998, *Oncogene* 17, 2473-84; Wang, J. et al., 1998, *Proc Natl Acad Sci U S A* 95, 10860-5). T3R for example was originally identified on the basis of its homology with the viral oncogene v-erbA, which in contrast to the wild type receptor does not bind ligand and functions as a constitutive repressor of transcription. Furthermore, mutations in RARs have been associated with a number of human cancers, particularly acute promyelocytic leukemia (APL) and hepatocellular carcinoma. In APL patients RAR fusion proteins resulting from chromosomal translocations involve either the promyelocytic leukemia protein (PML) or the promyelocytic zinc finger protein (PLZF). Although both fusion proteins can interact with components of the corepressor complex, the addition of retinoic acid dismisses the corepressor complex from PML-RAR, whereas PLZF-RAR interacts constitutively. These findings provide an explanation why PML-RAR APL patients achieve complete remission following retinoic acid treatment whereas PLZF-RAR APL patients respond very poorly (Grignani et al., 1998, *Nature* 391, 815-8; Guidez et al., 1998, *Blood* 91, 2634-42; He et al., 1998, *Nat Genet* 18, 126-35; Lin et al., 1998, *Nature* 391, 811-4). Furthermore, a PML-RAR patient who had experienced multiple relapses after treatment with retinoic acid has recently been treated with the HDAC inhibitor phenylbutyrate, resulting in complete remission of the leukemia (Warrell et al., 1998, *J. Natl. Cancer Inst.* 90, 1621-1625).

By now, a clinical phase II trial with the closely related butyric acid derivative Pivanex (Titan Pharmaceuticals) as a monotherapy has been completed demonstrating activity in stage III/IV non-small cell lung cancer (Keer et al., 2002, ASCO, Abstract No. 1253). More HDAC inhibitors have been identified, with NVP-LAQ824 (Novartis) and SAHA (Aton Pharma Inc.) being members of the structural class of hydroxamic acids tested in phase I clinical trials (Marks et al., 2001, *Nature Reviews Cancer* 1, 194-202). Another class comprises cyclic tetrapeptides, such as depsipeptide (FR901228 - Fujisawa) used successfully in a phase II trial for the treatment of T-cell lymphomas (Piekarz et al., 2001, *Blood* 98, 2865-8). Furthermore, MS-27-275 (Mitsui Pharmaceuticals), a compound related to the class of benzamides, is now being tested in a phase I trial patients with hematological malignancies.

The recruitment of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is considered as a key element in the dynamic regulation of many genes playing important roles in cellular proliferation and differentiation. Hyperacetylation of the N-terminal tails of histones H3 and H4 correlates with gene activation whereas deacetylation can mediate transcriptional repression. Consequently, many diseases have been linked to changes in gene expression caused by mutations affecting transcription factors. Aberrant repression by leukemia fusion proteins such as PML-RAR, PLZF-RAR, AML-ETO and Stat5-RAR serves as a prototypical example in this regard. In all of these cases, chromosomal translocations convert transcriptional activators into repressors, which constitutively repress target genes important for hematopoietic differentiation via recruitment of HDACs. It is plausible that similar events could also contribute to pathogenesis in many other types of cancer.

Mammalian histone deacetylases can be divided into three subclasses (Gray and Ekström, 2001). HDACs 1, 2, 3, and 8 which are homologues of the yeast RPD3 protein constitute class I. HDACs 4, 5, 6, 7, 9, and 10 are related to the yeast Hda 1 protein and form class II. Recently, several mammalian homologues of the yeast Sir2 protein have been identified forming a third class of deacetylases which are NAD dependent. All of these HDACs appear to exist in the cell as subunits of a plethora of multiprotein complexes. In particular, class I and II HDACs have been shown to interact with transcriptional corepressors mSin3, N-CoR and SMRT which serve as bridging factors required for the recruitment of HDACs to transcription factors.

#### *Molecular markers in cancer therapy*

The discovery of new molecular markers for diagnosis and staging of human cancer is still an ongoing task and is essential for choosing the right therapeutic strategy. In the case of breast cancer, molecular markers such as the level of HER2/neu, p53, BCL-2 and estrogen/progesterone receptor expression have been clearly shown to correlate with disease status and progression. A newly approved kit measuring HER2 concentration in the serum of patients with metastatic breast cancer can now be used for followup and monitoring of these patients. Several large studies have shown that HER2 serum concentration is related to severity of disease, and – more importantly - in patients who respond to therapy, HER2 concentration decreases, irrespective of type of therapy. This example demonstrates the value of diagnostic and prognostic markers in cancer therapy.

*Medical need for new diagnostic and prognostic tools related to HDAC inhibitors.*

The clinical benefits of HDAC inhibition and their implications for cancer therapy are currently being investigated in several locations. Although results from initial studies indicate that HDAC inhibitors may be beneficial in the treatment of acute myeloid leukemia, T-cell lymphoma, and lung cancer it is highly likely that other cancer entities may be effectively treated. As yet, many of the HDAC inhibitors under investigation have often side effects demanding further development of new generation HDAC inhibitors. It is therefore essential to identify a characteristic profile for successful candidates as HDAC inhibitors. This may have dramatic consequences for saving cost and time in the development of new compounds. The second major task will then be to identify early on patients who will benefit from a therapy with these HDAC inhibitors and to monitor these patients during therapy. Both questions will be addressed in the present patent application.

The present invention aims at providing diagnostic and prognostic tools for the development and use of HDAC inhibitors. It has surprisingly been found that the level of certain proteins in cells treated with the HDAC inhibitor Valproic acid (VPA) is upregulated or downregulated in dependence of VPA treatment. These proteins or the RNA encoding them can be used as molecular markers. Therefore, one aspect of the present invention is the use of specific molecular markers for the profiling of HDAC inhibitors.

The invention relates to a method for the characterization of an HDAC inhibitor or a potential HDAC inhibitor comprising, determining in a sample the amount of a molecular marker, wherein the sample is derived from cells which have been treated with said HDAC inhibitor or potential HDAC inhibitor.

The term "molecular marker" as used herein designates a gene product, i.e. a protein or a ribonucleic acid including mRNA expressed from said gene, wherein the amount of said gene product in a cell is upregulated or downregulated by the HDAC inhibitor VPA in cell lines such as HEK 293T, F9, K562, HL60, and leukemic bone marrow. For example, VPA regulates expression of HDAC-2 and BCL-X<sub>L</sub>, p21 (WAF), UBC8, RLIM, CASPASE 8, and TRAIL. Preferred markers according to the invention are HDAC-2 protein, Ubc8 RNA, UBC8 protein, RLIM protein, TRAIL RNA and TRAIL protein.

The "characterization of an HDAC inhibitor or potential HDAC inhibitor" encompasses the identification of patients and tumor entities that respond to a therapy with said HDAC

inhibitors or potential HDAC inhibitors; monitoring efficacy of HDAC inhibitor treatment in patients; predicting therapeutic responses to HDAC inhibitors; profiling of HDAC inhibitors or potential HDAC inhibitors; and diagnosing diseases such as colon cancer.

The sample is a composition derived from cells which have been treated with an HDAC inhibitor or a potential HDAC inhibitor. The cells may be cell culture cells which have been contacted with said HDAC inhibitor or potential HDAC inhibitor. The inhibitor can be added to the growth medium of the cells. This embodiment is particularly suited for the profiling of HDAC inhibitors or potential HDAC inhibitors.

Another aspect of the present invention is the use of the above listed molecular markers to identify patients and tumor entities that respond to a therapy with these HDAC inhibitors. Furthermore, these markers can be used to monitor efficacy of HDAC inhibitor treatment in patients. Prognostic and diagnostic monitoring is suitable for diseases in which the induction of hyperacetylation of histones or other molecules has a beneficial effect resulting in differentiation and/or apoptosis of a patient's tumor cells and thus causing a clinical improvement of the patient's condition.

The cells may therefore also be derived from a tissue of an individual that was treated with an HDAC inhibitor. In this embodiment, the sample is preferably derived from tissue affected by a disorder. A tissue affected by a disorder is a tissue which differs from the corresponding tissue of a healthy individual. The difference may be a difference in morphology, histology, gene expression, response to treatment or protein composition etc. The tissue affected by the disorder may be tumor tissue in the case of cancer disease derived from but not restricted to bone marrow, colon, skin, breast, ovaries, prostate, kidney, bladder, esophagus, stomach, brain, lung, lymph nodes, and pancreas. Examples of such diseases include but are not limited to, skin cancer, melanoma, estrogen receptor-dependent and independent breast cancer, ovarian cancer, testosterone receptor-dependent and independent prostate cancer, renal cancer, colon and colorectal cancer, pancreatic cancer, bladder cancer, esophageal cancer, stomach cancer, genitourinary cancer, gastrointestinal cancer, uterine cancer, astrocytomas, gliomas, basal cancer and squamous cell carcinoma, sarcomas as Kaposi's sarcoma and osteosarcoma, head and neck cancer, small cell and non-small cell lung carcinoma, leukemia, lymphomas and other blood cell cancers.

The invention encompasses also the use of these markers for monitoring treatment of minimal residual tumor disease or tumor metastases.

Yet another aspect of the invention is the use of these markers in diseases that show aberrant recruitment of histone deacetylase activity such as thyroid resistance syndrome, or other conditions associated with abnormal gene expression, such as inflammatory disorders, diabetes, thalassemia, cirrhosis, protozoal infection, or the like and all types of autoimmune diseases, in particular rheumatoid arthritis, rheumatoid spondylitis, all forms of rheumatism, osteoarthritis, gouty arthritis, multiple sclerosis, insulin dependent diabetes mellitus and non-insulin dependent diabetes, asthma, rhinitis, uveitis, lupus erythematosus, ulcerative colitis, Morbus Crohn, inflammatory bowel disease, as well as other chronic inflammations, chronic diarrhea.

Furthermore, the invention concerns the diagnostic and prognostic use of the above mentioned markers in other proliferative diseases such as psoriasis, fibrosis and other dermatological disorders. The terms "proliferative disease", and "cell proliferation", are used interchangeably herein and relate to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether *in vitro* or *in vivo*. Examples of proliferative conditions include, but are not limited to, pre-malignant and malignant cellular proliferation, including malignant neoplasms and tumors, cancers, leukemias, psoriasis, bone disease, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Any type of cell may be treated, including but not limited to, lung, colon, breast, ovarian, prostate, liver, pancreas, brain, and skin and any treatment of disorders involving T-cells such as aplastic anemia and DiGeorge syndrome, Graves' disease.

The cells are usually processed to be in a condition which is suitable for the method employed in determining the amount of molecular marker. Processing may include homogenization, extraction, fixation, washing and/or permeabilization. The way of processing largely depends on the method used for determination of the amount of molecular marker. The sample may be derived from a biopsy of the patient. The biopsy may be further treated to yield a sample which is in a condition suitable for the method used for determining the amount of molecular marker.



A variety of methods can be employed to determine the amount of molecular marker in the sample. The type of method to be used depends on the nature of the molecular marker. When the molecular marker is a protein the amount of the molecular marker is preferably determined by use of an antibody directed against the molecular marker.

As used herein, the term "antibody" designates an immunoglobulin or a derivative thereof having the same binding specificity. The antibody used according to the invention may be a monoclonal antibody or an antibody derived from or comprised in a polyclonal antiserum, monoclonal antibodies are preferred. The term "antibody", as used herein, further comprises derivatives such as Fab, F(ab')<sub>2</sub>, Fv, or scFv fragments: see, for example Harlow and Lane, "Antibodies, A Laboratory Manual" CSH Press 1988, Cold Spring Harbor N.Y. The antibody or the derivative thereof may be of natural origin or may be (semi)synthetically produced. Such synthetic products also comprises non-proteinaceous or semi-proteinaceous material that has the same or essentially the same binding specificity as the antibody of the invention. Such products may, for example be obtained by peptidomimetics. Methods of producing antibodies directed against the molecular marker proteins are known in the art (Harlow and Lane, "Antibodies, A Laboratory Manual" CSH Press 1988, Cold Spring Harbor N.Y.). The amino acid sequences of the molecular markers HDAC-2 protein, UBC8 protein, RLIM protein and TRAIL protein are described in Yang, W.M. et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93, 12845-12850; Kaiser, P. et al., 1994, J. Biol. Chem. 269, 8797-8802; Ostendorff, H.P et al., 2000, Genomics 69, 120-130; Wiley, S.R. et al., 1995, Immunity 3(6), 673-682;; Mariani, S.M. et al., 1997, J Cell Biol 137, 221-229, respectively. The amino acid sequences of the molecular markers HDAC-2 protein, UBC8 protein, RLIM protein and TRAIL protein are shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, respectively. The antibody may be used in methods which are known to those skilled in the art, e.g. Western Blotting, ELISA, immunohistochemistry and/or flow cytometry.

Western Blotting may be used which is generally known in the art. The cellular material or tissue may be homogenized and treated with denaturing and/or reducing agents to obtain the samples. The sample may be loaded on a polyacrylamide gel to separate the proteins followed by transfer to a membrane or directly be spotted on a solid phase. The antibody is then contacted with the sample. After one or more washing steps the bound antibody is detected using techniques which are known in the art. Gel electrophoresis of proteins and

Western Blotting is described in Golemis, "Protein-Protein Interactions: A Laboratory Manual", CSH Press 2002, Cold Spring Harbor N.Y.

Immunohistochemistry may be used after fixation and permeabilisation of tissue material, e.g. slices of solid tumors. The antibody is then incubated with the sample, and following one or more washing steps the bound antibody is detected. The techniques are outlined in Harlow and Lane, "Antibodies, A Laboratory Manual" CSH Press 1988, Cold Spring Harbor N.Y..

In a preferred embodiment, the amount of molecular marker is determined by way of an ELISA. A variety of formats of the ELISA can be envisaged. In one format, the antibody is immobilized on a solid phase such as a microtiter plate, followed by blocking of unspecific binding sites and incubation with the sample. In another format, the sample is first contacted with the solid phase to immobilize the molecular marker proteins contained in the sample. After blocking and optionally washing, the antibody is contacted with the immobilized sample. ELISA techniques are described in Harlow and Lane, "Antibodies, A Laboratory Manual" CSH Press 1988, Cold Spring Harbor N.Y..

Most preferably, the amount of molecular marker is determined by flow cytometry. Cells, e.g. cell culture cells or blood cells or cells from bone marrow, are fixed and permeabilized to allow the antibody to reach the molecular marker proteins. After optional washing and blocking steps the antibody is contacted with the cells. Flow cytometry is then performed in accordance with procedures known in the art in order to determine cells having antibody bound to molecular marker proteins. Various flow cytometry methods are described in Robinson "Current Protocols in Cytometry" John Wiley & Sons Inc., New York.

When the molecular marker is a ribonucleic acid such as mRNA, nucleic acid technologies are usually employed to determine the amount of molecular marker in the sample. Preferably hybridization techniques and/or PCR techniques are employed. Northern blotting techniques may be used to determine the amount of RNA marker in the sample. In a preferred embodiment, RT-PCR is used. The man skilled in the art is able to design suitable primers and/or probes to be used in these methods on the basis of the nucleotide sequences of the respective markers. The cDNA sequences of Ubc8, RLIM and TRAIL are described in Wiley, S.R. et al., 1995, Immunity 3(6), 673-682; Mariani, S.M. et al., 1997, J Cell. Biol. 137, 221-229; Kaiser, P. et al., 1994, J. Biol. Chem. 269, 8797-8802,

Ostendorff, H.P et al., 2000, Genomics 69, 120-130; respectively. Methods how to design primers and probes are described in Dieffenbach "PCR Primer: A Laboratory Manual" CSH Press 1995, Cold Spring Harbor N.Y.. The cDNA sequences of HDAC-2, Ubc8, RLIM and TRAIL are shown in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, respectively.

In a further embodiment, the method comprises the step of selecting the inhibitor if it has the activity of modulating the expression of the molecular marker. "Modulating the expression of the molecular marker" as used herein designates the capability or activity of a compound to induce upon contact with a cell an increase or decrease in the amount of molecular marker in the cell. To determine whether an HDAC inhibitor or potential HDAC inhibitor has this activity, one usually determines the amount of molecular marker in a reference sample wherein the reference sample is derived from cells which have not been treated with said HDAC inhibitor or potential HDAC inhibitor. The determination of the amount of molecular marker in the sample and in the reference sample may be performed in parallel. In the case of cell culture cells, two cellular compositions are provided, one of which is treated with HDAC inhibitor or potential HDAC inhibitor, whereas the other is left untreated. Subsequently both compositions are further processed and the respective amounts of molecular marker are determined.

In the case of patients, the sample is derived from a patient which has been treated with HDAC inhibitor or potential HDAC inhibitor. The reference sample is derived from another patient suffering from the same disorder who has not been treated with said HDAC inhibitor or potential HDAC inhibitor or from a healthy individual. The tissue from which this reference sample is derived corresponds to the tissue from which the sample is derived. For example, if the sample is derived from tumor tissue from a breast cancer patient the reference sample is also derived from tumor tissue from a breast cancer patient or from breast tissue from a healthy individual. It may also be envisaged that the sample and the reference sample are derived from the same individual. In this case, the tissue, from which the reference sample is derived was obtained from the individual prior to or after treatment of the individual with an HDAC inhibitor. Preferably, the tissue was obtained prior to the treatment to exclude possible after-effects of the inhibitor treatment on the expression of the molecular marker after discontinuation of the treatment.

Another aspect of the invention is the use of a means for determining the amount of a molecular marker for profiling of HDAC inhibitors or potential HDAC inhibitors.

Methods for determining the amount of a molecular marker have been described supra. Thus, preferred means for determining the amount of a molecular marker are antibodies directed against molecular marker proteins, primers which can be used to amplify molecular marker RNA or cDNA derived therefrom, probes which are capable of specifically hybridizing to molecular marker RNA or cDNA derived therefrom. The most preferred means include antibodies directed against TRAIL protein, HDAC-2 protein, RLIM or Ubc8 protein; primers capable of specifically amplifying TRAIL RNA, TRAIL cDNA, Ubc8 RNA or Ubc8 cDNA; and probes capable of specifically hybridizing to TRAIL RNA, TRAIL cDNA, Ubc8 RNA or Ubc8 cDNA under standard conditions. The primers and probes are usually oligonucleotides having a length of 10 to 50 nucleotides, preferably 15 to 30 nucleotides, more preferably 15 to 24 nucleotides. In one embodiment the oligonucleotides hybridize to the respective target sequence under conditions such as 0.1xSSC, 0.1% SDS and 65°C. The setting of appropriate conditions is described in Sambrook et al., "Molecular Cloning, A Laboratory Manual, 1989; or Hames and Higgins. "Nucleic acid hybridization, a practical approach", IRL press, 1985.

In a specific embodiment, the oligonucleotides used in accordance with the invention comprise or consist of 10 to 50, preferably 15 to 24 contiguous nucleotides of a polynucleotide selected from the group consisting of HDAC-2 cDNA, Ubc8 cDNA, RLIM cDNA, TRAIL cDNA, and complements thereof. Examples are oligonucleotides comprising or consisting of 10 to 50 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and complements thereof.

Specific examples of primers capable of amplifying a molecular marker are the following:

HDAC-2:

forward	5'-ggagaagattgtccagcgtt-3'
reverse	5'-ctataccatcacacattgga-3'

UBC8:

forward	5'-ggtcaagctcatcgagagta-3'
reverse	5'-tcagcgctcctccgtggcg-3'

## RLIM:

forward 5'-cagagggtcccacctaccaga-3'

reverse 5'-ctatgctatctctctgccga-3'

## TRAIL:

forward 5'-gggacagacctgcgtgctga-3'

reverse 5'-ctccttgatgattcccagga-3'

In yet another aspect the invention concerns the use of a means for determining the amount of a molecular marker for diagnosing a disease. Preferably, means for determining the amount of HDAC-2 protein are used for diagnosing colon cancer. In particular, the invention relates to the use of an antibody directed against HDAC-2 protein for diagnosing colon cancer.

The invention further relates to the use of a means for determining the amount of a molecular marker for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not. This aspect includes the identification of patients and tumor entities that respond to a therapy with said HDAC inhibitor or potential HDAC inhibitor, monitoring efficacy of HDAC treatment in patients; predicting therapeutic response to HDAC inhibitors; and diagnosing diseases such as colon cancer.

The invention also concerns a diagnostic kit containing (i) means for determining the amount of a molecular marker; and (ii) an HDAC inhibitor. The preferred embodiments of the kit correspond to the preferred embodiments of the method or use of the invention as described supra.

Preferably, the method or use of the invention comprises only steps which are carried out *in vitro*. Therefore, according to this embodiment the step of obtaining the tissue material from the human or animal body is not encompassed by the present invention.

*Selective proteosomal degradation of HDAC-2 by HDAC inhibitors*

Cancer therapy using HDAC inhibitors induces differentiation and/or apoptosis in tumor cells. This is achieved in a process involving hyperacetylation of HDAC-dependent substrates, such as histones and transcription factors (e.g. the tumor suppressor p53,

which in turn regulate expression of genes that promote differentiation or apoptosis. The present invention therefore also relates to the ability of certain HDAC inhibitors to induce the expression of the E2 ubiquitin conjugating enzyme Ubc8, and the concomitant specific proteasomal degradation of the iso-enzyme HDAC-2 via the E3 ubiquitin ligase RLIM, which adds a novel aspect to the activity of certain HDAC inhibitors, such as Valproic acid, acting synergistically with the enzymatic inhibition of histone deacetylases.

This invention also concerns the diagnostic use of Ubc8 and HDAC-2 expression in tumors from patients to predict therapeutic response to HDAC inhibitors, such as Valproic acid, which upregulate Ubc8 and downregulate HDAC-2 expression. It also includes the use of HDAC-2 expression in tumors to monitor efficacy of certain HDAC inhibitors, such as Valproic acid, in the course of therapy.

Furthermore, a particular aspect of the present invention relates to the profiling of HDAC inhibitors or compounds with assumed HDAC inhibitory activity for their ability to downregulate HDAC-2 and/or RLIM expression and upregulate Ubc8 expression. Methods to analyse expression of HDAC-2, RLIM and Ubc8 comprise the use of nucleic acid technology, preferably of hybridization or polymerase chain reaction for detection. Other types of nucleic acid technology, however, may be employed. In another embodiment of the invention the method comprises the use of specific antibodies against the above mentioned proteins for detection.

*Molecular markers for apoptotic pathways induced by HDAC inhibitors*

Normal cells have an intrinsic mechanism of self destruction called programmed cell death or apoptosis. This balance is often disturbed in cancer cells inducing too much growth and too little death (Igney and Kramer, 2002, Nature Reviews Cancer 2:277-288). Understanding of these mechanisms at the molecular level does, ultimately, lead to new therapeutic approaches based on modulation of apoptosis sensitivity. Apoptosis can be induced by activation of, so called, death receptors that belong to the tumor-necrosis factor (TNF) receptor superfamily. Death receptors are activated by their natural ligands, the TNF family, including TNFalpha, CD95L and TRAIL. This leads to activation of a death-inducing signaling complex (DISC) containing caspase 8 which – in turn – induces apoptosis. Upregulation of any member of this pathway enhances the effect of pro-apoptotic signals.

The apoptotic process is tightly controlled by various regulatory proteins, such as the members of mitochondrial BCL2 family being among the most important. BCL2 family members can be divided into anti-apoptotic, such as BCL2, BCL-XL, BCL-w, and pro-apoptotic proteins, such as BAX, BAK, BID, BAD. Anti-apoptotic BCL2 family members seem to be involved in resistance of tumors to apoptosis. For example, BCL-XL can confer resistance to multiple apoptosis-inducing pathways in cancer cells and seems to be upregulated by a constitutively active epidermal growth factor receptor. High expression of BCL-XL is found in many human cancers and is often a negative prognostic factor. Accordingly, downregulation of BCL-XL expression in certain cancer cells either induces apoptosis directly or sensitizes cells to apoptotic stimuli.

This present invention relates to the ability of certain HDAC inhibitors, such as Valproic acid, to specifically induce the expression of the pro-apoptotic molecules TRAIL and Caspase 8 and to downregulate the expression of the anti-apoptotic molecule BCL-XL in cancer cells, which provides a deeper insight into the mechanism of induction of apoptosis and sensitization to apoptotic stimuli induced by these HDAC inhibitors. Additionally, the invention concerns the diagnostic use of TRAIL, Caspase 8 and BCL-XL expression in tumors from patients to predict therapeutic response to HDAC inhibitors, such as Valproic acid, that upregulate TRAIL and Caspase 8 expression and downregulate BCL-XL expression. It also includes the use of TRAIL, Caspase 8 and BCL-XL expression in tumors to monitor the efficacy of certain HDAC inhibitors, such as Valproic acid, in the course of therapy.

In yet another embodiment the invention relates to the profiling of HDAC inhibitors or compounds with assumed HDAC inhibitory activity for their ability to downregulate BCL-XL expression and upregulate TRAIL and Caspase 8 expression. Methods to analyse TRAIL, Caspase 8, and BCL-XL expression comprise the use of nucleic acid technology, preferably of hybridization or polymerase chain reaction for detection. Other types of nucleic acid technology, however, may be employed. In another embodiment the method comprises the use of specific antibodies against the above mentioned proteins for detection.

**Figure 1:** VPA enhances survival of acute promyelocytic leukemia mice (Figure 1A) and reduced splenomegaly in acute promyelocytic leukemia mice after treatment with VPA (Figure 1B) (Example 1).

**Figure 2:** Histone hyperacetylation in splenocytes in normal and leukemic mice after treatment with VPA (400 mg/kg) for three and six hours (Figure 2A and B) (Example 1).

**Figure 3:** VPA induces apoptosis in leukemic cells, but not in normal splenocytes in vivo (Figure 3A) and in vitro (Figure 3B) (Example 1).

**Figure 4:** VPA induces TRAIL expression in leukemic cells in vivo (Figure 4A), and in non-leukemic tumor cell lines in vitro (Figure 4B) (Example 1).

**Figure 5:** Inhibition of TRAIL and caspase 8 impair VPA-induced apoptosis of murine APL blasts (Example 1).

**Figure 6:** VPA but not TSA induces reduction of HDAC-2 protein levels (Example 2).

**Figure 7:** VPA does not change HDAC-2 mRNA levels (Example 2).

**Figure 8:** Induction of HDAC-2 protein degradation by VPA (Example 2).

**Figure 9:** Proteasome inhibitors but not protease inhibitors inhibit VPA induced HDAC-2 degradation (Example 2).

**Figure 10:** HDAC-2 is ubiquitinated in response to VPA treatment (Example 2).

**Figure 11:** VPA induces expression of the E2 ubiquitin conjugase Ubc8 (Example 3).

**Figure 12:** The HDAC inhibitor TSA, but not VPA induces proteosomal degradation of the E3 ubiquitinating enzyme RLIM (Example 3).

**Figure 13:** Identification of E3 ubiquitinating enzyme, RLIM to induce ubiquitination of HDAC's 1-3 (Example 3).



**Figure 14:** HDAC-2 is upregulated in human colon cancer tissues (Example 4).

The following examples further illustrate the invention:

#### **EXAMPLE 1**

HDAC inhibitors induce TRAIL expression, Caspase 8 activation and apoptosis in cancer cells but not normal blood cells (Figure 1-5).

Although the discrete mechanism of action varies, cancer therapy still depends on an ability to engender apoptosis in cancer cells as a final common pathway. HDAC inhibitors have already been shown to induce apoptosis in certain cancer cells through down-regulation of the anti-apoptotic molecules, such as BCL-XL and BCL-2. In general, induction of apoptosis can be exploited therapeutically using HDAC inhibitors in cancer therapy. We present new evidence that HDAC inhibitors (namely Valproic acid - VPA) can be used in cancer treatment using a mouse leukemia model of acute promyelocytic leukemia (APL; Figure 1). We demonstrate that HDAC inhibitors such as VPA, induce histone hyperacetylation (Figure 2) and apoptosis (Figure 3) in leukemic cells from mice with APL. According to the present invention, HDAC inhibitors (namely Valproic acid) induce apoptosis in leukemic cells cancer cells by upregulating TRAIL expression and activating caspase 8. This process is not seen in normal cells.

#### **METHODS**

**Figure 1:** (A) Secondary acute promyelocytic leukemias were induced in mice. In brief, primary leukemias were induced in mice by injecting PML/RAR expressing bone marrow cells into the tail veins. Mice with overt leukemias were euthanized, and leukemic cells were harvested from the spleen. Leukemic cells were re-injected i.v. ( $1 \times 10^7$  cells/mouse) in non-irradiated, syngeneic recipient mice. The secondary recipient mice developed overt leukemia in about 2-3 weeks. Leukemic mice or healthy mice (Ctrl) were then treated with placebo (lanes 1, 3), or VPA (400 mg/kg every 12 hours) for two consecutive weeks. (B) Leukemic mice were treated with placebo (lower, Ctrl) or VPA (400 mg/kg every twelve hours, upper) for one week. At the end of the treatment, mice were sacrificed, and spleens were photographed.

**Figure 2:** (A) Secondary acute promyelocytic leukemias were induced in mice as described above. (A) Leukemic mice or healthy mice (Ctrl) were then treated with placebo or VPA (400 mg/kg) for three and six hours. Mice were then sacrificed, whole cell extracts were prepared from the spleen (with >70% leukemic infiltration), and analyzed by SDS-PAGE followed by Western blot analysis using commercially available antibodies against acetylated histone H3. (B) Immunohistochemistry analysis of VPA-treated leukemic mice using a monoclonal antibody against acetylated histones.

**Figure 3:** (A) Secondary acute promyelocytic leukemias were induced in mice as described above. Leukemic mice were then treated with placebo (Ctrl), or VPA (400 mg/kg every 12 hours). Mice were sacrificed 48 hours after beginning of treatments, and then leukemic spleens were fixed and either stained for histological examination (hematoxylin-eosyn, left panels), or analyzed for the presence of apoptotic cells (TUNEL assay, right panels). (B) Secondary leukemias were obtained as above. Mice were sacrificed when leukemic invasion of peripheral organs was >75% (spleen). Splenocytes from healthy mice (taken as control, left panel), or from leukemic mice (>75% blasts, right panel) were put in culture and then treated with VPA (1mM) for 48 hours. At the end of the treatment, apoptosis was measured by propidium iodide staining. The sub-G1 area indicates the hypodiploid DNA peak corresponding to cells with fragmented DNA undergoing apoptosis.

**Figure 4:** (A) Secondary acute promyelocytic leukemias were induced in mice as described above. Leukemic mice or healthy mice (Ctrl) were then treated with placebo (lanes 1, 3), VPA (400 mg/kg every 12 hours), all-trans retinoic acid (a 21-day-release pellet containing 5 mg RA or placebo: lanes 8-9), and VPA plus retinoic acid (lanes 10-11). Mice were sacrificed 18 hours (lanes 4-5), or 36 hours after beginning of treatment (lanes 3, 6-7, 10-11): total RNAs were collected from the spleens (with a >75% invasion of leukemic blasts as assessed by Giemsa staining) and analyzed by RNase protection assay to check for expression of TRAIL. *Faf* and *GAPDH* were used as controls, not affected by these treatments. (B) Calu-3 cells (a human, non-small cell lung cancer derived cell line) were treated with VPA (1mM) for the indicated times. RNA was extracted and analyzed by quantitative

PCR (Perkin-Elmer), using primers specific for TRAIL. GAPDH was used to normalize.

**Figure 5:** Leukemic blasts were obtained from spleens of secondary leukemic mice with a >75% invasion of tumor cells, as assessed by histological examination. Cells were put in culture and treated with VPA (1mM) for 48 hours, in the absence or in the presence of the indicated TRAIL and/or caspase 8 inhibitors as indicated. At the end of the treatment, apoptosis was measured as described above.

## RESULTS

Efficacy of HDAC inhibitor treatment was tested in a mouse leukemia model. Survival curves of mice with overt secondary leukemia showed that VPA treatment extended survival of leukemic mice in a statistically significant way ( $P < 0.01$ , Figure 1A). Additionally, VPA caused a dramatic reduction in the splenomegaly caused by blast infiltration (compare placebo with VPA-treated, Figure 1B). To further analyze the activity of HDAC inhibitor treatment we used whole cell extracts prepared from the spleen (either normal spleen or leukemic spleen with >70% leukemic infiltration). VPA induces enhanced levels of histone acetylation both in normal mice, and in leukemic mice (Figure 2A). Furthermore, immuno-histochemistry analysis of VPA-treated leukemic mice using a monoclonal antibody against acetylated histones shows dramatic increase of histone acetylation in all cells upon VPA treatment, including leukemic blasts (Figure 2B). Cells obtained from leukemic spleens were then analyzed for the presence of apoptotic cells after treatment with or without VPA (TUNEL assay, Figure 3A, right panels). The results show that VPA induces massive apoptosis within leukemic spleens. To confirm these data, splenocytes from healthy mice (taken as control, Figure 3B, left panel), or from leukemic mice (>75% blasts, Figure 3B, right panel) were put in culture and then treated with VPA (1mM) for 48 hours. At the end of the treatment, apoptosis was measured by propidium iodide staining showing that VPA induces massive apoptosis of leukemic cells, but it is unable to induce apoptosis of normal splenocytes.

To understand the pathomechanism of selective induction of apoptosis in cancer cells, we investigated whether HDAC inhibitor treatment enhance TRAIL expression. As shown in figure 4A, whereas *in vivo* VPA treatment did not cause induction of TRAIL expression in the spleens of healthy mice (lanes 1-2), it induced TRAIL for the entire duration of treatment in two independent sets of leukemic mice analyzed (lanes 3-5, experiment 1;

lanes 6-7, experiment 2) as strongly as upon 96 hours of retinoic acid treatment (lanes 8-9). Combined RA+VPA treatment did not further increase TRAIL expression (lanes 10-11). Furthermore, as shown in figure 4B, TRAIL is strongly induced in human CaLu-3 cancer cells by the treatment with VPA, demonstrating that TRAIL is also a target of VPA in non-leukemic cancer cells, and extending the principle that TRAIL induction as a consequence of VPA treatment may be broadly responsible for the induction of cell death in tumor cells. This was confirmed in experiments where leukemic cells could be rescued from apoptosis by inhibitors of TRAIL or caspase 8. As can be seen from the data of Figure 5, in experiments where the inhibition of TRAIL by a TRAIL receptor/Fc chimera (able to titrate out active TRAIL, and impairing signaling through the endogenous receptor), or by a caspase 8 inhibitor (directly blocking activation of caspase 8, downstream of activated TRAIL), was able to block partially (single treatments) or entirely (combined treatment) the effect of VPA, showing that the TRAIL pathway is a critical effector of VPA action.

## **EXAMPLE 2**

Valproic acid defines a class of HDAC inhibitors that induce proteosomal degradation of HDAC-2 (Figure 6-10).

The recruitment of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is considered as a key element in the dynamic regulation of many genes playing important roles in cellular proliferation and differentiation. Hyperacetylation of the N-terminal tails of histones H3 and H4 correlates with gene activation whereas deacetylation can mediate transcriptional repression. Consequently, many diseases have been linked to changes in gene expression caused by mutations affecting transcription factors. Aberrant repression by leukemia fusion proteins such as PML-RAR, PLZF-RAR, AML-ETO and Stat5-RAR serves as a prototypical example in this regard, but it is becoming increasingly evident that similar events contribute to pathogenesis in many other types of cancer.

Mammalian histone deacetylases can be divided into three subclasses (Gray and Ekström, 2001). HDACs 1, 2, 3, and 8 which are homologues of the yeast RPD3 protein constitute class I. HDACs 4, 5, 6, 7, 9, and 10 are related to the yeast Hda 1 protein and form class II. Recently, several mammalian homologues of the yeast Sir2 protein have been identified forming a third class of deacetylases which are NAD dependent. All of these HDACs appear to exist in the cell as subunits of a plethora of multiprotein complexes. In particular,

class I and II HDACs have been shown to interact with transcriptional corepressors mSin3, N-CoR and SMRT which serve as bridging factors required for the recruitment of HDACs to transcription factors.

The proteasome is widely recognised as the central enzyme complex of non-lysosomal protein degradation being an essential component of the ATP-dependent proteolytic pathway catalysing the rapid degradation of many rate-limiting enzymes, transcriptional regulators and critical regulatory proteins. It is essential for the rapid elimination of highly abnormal proteins, arising via mutation or by post-translational damage, and plays a primary role in the slower degradation of the bulk of proteins in mammalian cells. It is also critically involved in higher eukaryotes in antigen processing.

The present invention demonstrates the ability of certain HDAC inhibitors, in particular valproic acid, to selectively induce degradation of the HDAC-2 protein additionally to their HDAC inhibitory activity. This selective reduction in HDAC-2 protein levels is seen after stimulation with valproic acid and butyric acid but not with other HDAC inhibitors such as trichostatin A, trapoxin, and MS-275. Thus, HDAC inhibitors such as valproic acid inactivate HDAC-2 through two different mode of actions: they inhibit HDAC-2 activity and induce proteasomal degradation. The measurement of these combined activities may serve as a profiling tool for the identification of novel, and potentially more potent, inhibitors of enzymes having HDAC activity.

## METHODS

**Figure 6:** (A) F9 teratocarcinoma or HEK293T embryonic kidney cells were exposed for indicated times to 1 mM VPA. Protein levels of HDAC-2 and HDACs 1 or 3 for reference (HDAC8; N-CoR and Sin3 as data not shown) were determined by Westernblot analysis. (B) The dependency of reduction of HDAC-2 protein levels on the VPA dose was determined in F9 or HEK293T cells after 36 h of exposure. (C) The effect of other HDAC inhibitors on the amount of HDAC-2 protein was determined by using TSA (100 nM) in a time course analysis in F9 cells (left panel). The HDAC inhibitors TSA (100 nM), trapoxin (TPX, 10 nM), butyrate (1.5 mM) or MS275 (5  $\mu$ M) were tested at a single time of exposure in HEK293T cells (right panel).

**Figure 7:** F9 cells or HEK 293T cells were treated for indicated times with 1 mM VPA and the levels of HDAC-2 mRNA were determined by Northern blot analysis from 5  $\mu$ g polyA<sup>+</sup> RNA.

**Figure 8:** Synthesis and degradation rate of HDAC-2 were analyzed by pulse metabolic labeling with <sup>35</sup>S-methionine and pulse-chase analyses. <sup>35</sup>S-labelled HDAC-2 was detected by HDAC-2 specific immune precipitation followed by SDS-PAGE separation and autoradiography. (A) Pulse labeling for 1 h was performed in F9 and HEK293T cells which had been left untreated or were pretreated with 1 mM VPA for 24 h. (B) For pulse chase analysis cells were left untreated or pretreated for 24 h with 1 mM VPA and labeled with <sup>35</sup>S-methionine for an additional hour in the absence or presence of VPA. After removal of <sup>35</sup>S-methionine and addition of non-labeled methionine the elimination of radiolabeled HDAC-2 was followed over a period of 6 h. A pulse chase analysis was also performed in HEK293T cells without VPA pretreatment and addition of VPA (indicated by the (+) row) only at the time when the chase period was started. From HEK293T cell extracts also HDAC-3 was precipitated for reference.

**Figure 9:** (A) HEK293T cells were treated for 24 h with VPA or left untreated. The cell penetrating protease inhibitors pepstatin A, leupeptin, or ALLM were added as indicated at the time of VPA addition. (B) Proteasome inhibitors ALLN or MG-132 were added at the indicated concentrations 4 h before cells were harvested. Protein levels of HDAC-2 were determined by Westernblot analysis.

**Figure 10:** (A) The total amount of high molecular weight poly-ubiquitinated protein was not altered by VPA treatment of cells (left two lanes). The presence of ubiquitinated proteins in anti HDAC-2 immune precipitates is shown in the right part of the panel. Cells had either been left untreated, were exposed to VPA (1.5 mM, 24 h) or the proteasome inhibitor ALLN (5  $\mu$ M, 24 h) or both. Ubiquitinated proteins in the precipitates were detected by Western blot analysis. For lane N a non-immune serum was used instead of the anti HDAC-2 antibody. (B) The presence of mono- and/ or oligo-ubiquitinated HDAC-2 upon VPA treatment of HEK293T cells was determined by ectopic expression of His<sub>6</sub>-tagged ubiquitin followed by VPA-treatment for 36 h as indicated. The proteasome inhibitor MG-132 was added 4 h prior to analysis to enhance the accumulation of

ubiquitinated proteins. Electrophoretic mobility and unaltered presence of non-ubiquitinated HDAC-2 were determined by Westernblot analysis of whole cell extracts (left panel). Ubiquitinated proteins were precipitated with  $\text{Ni}^{2+}$ -NTA-agarose and analyzed for presence of ubiquitinated HDAC-2 (middle panel) by Westernblot analysis of precipitates. Anti-HDAC-2 immuno-reactive bands with the expected mobility of mono- or poly-ubiquitinated HDAC-2 are indicated by a bracket. Westernblots of precipitates were also probed with an antibody directed against the poly-histidine tag (right panel) to assure comparable expression of tagged ubiquitin and equal efficiency of incorporation of tagged ubiquitin into the general cellular pool of ubiquitinated proteins in control and VPA-treated cells.

## RESULTS

### *Reduction of HDAC-2 protein levels by VPA treatment of cells and mice*

In the course of testing whether VPA or other HDAC inhibitors would also, in addition to inhibiting HDAC enzyme activities, affect expression or HDAC protein levels e.g. in a compensatory feed-back loop, we found a consistent down-regulation of HDAC-2 protein levels in VPA treated cells. Reduction of protein levels to about 30 % of untreated cells is found after 24 h of VPA exposure and persists at least for up to 48 h (Figure 6A). HDAC-2 protein levels are reduced in murine F9 teratocarcinoma, human embryonic kidney HEK293T cells (Figure 6A), human K562 leukemia cells and mouse NIH3T3 cells. Protein levels of HDAC-1, HDAC-3, are not reduced but show, in some experiments, a transient induction (Figure 6A). HDAC-2 protein levels show a delayed response to VPA exposure suggesting the need for intermediary steps, e.g. the induction of intermediary gene products. VPA doses required for reduction of HDAC-2 protein levels are similar to those required for inhibition of HDAC enzyme activity, e.g. clear effects are detected at 0.5 to 1 mM. In some cells such as HEK 293T that tolerate higher doses of VPA a slightly more pronounced reduction is found if VPA concentrations are increased up to 5 or 10 mM (Figure 6B).

Reduction of HDAC-2 protein levels is specific for carboxylic acid HDAC inhibitors such as VPA, Butyrate and EXHA. Treatment with the hydroxamic acid TSA for up to 48 h does not reduce HDAC-2 levels in either F9 or HEK293T cells (Figure 6C). In F9 cells 48 h TSA is toxic as documented by cell loss and reduction in the actin loading control. The VPA-derived amide valpromide which does not inhibit HDACs does not affect HDAC-2 protein

levels. Neither the cyclic tetrapeptide HDAC inhibitor trapoxin nor the anilide-based HDAC inhibitor MS-275 induces reduction of HDAC-2 protein levels.

However, under conditions that lead to reduction of HDAC-2 protein levels no response of HDAC-2 mRNA levels was found neither in F9 nor in HEK293T cells (Figure 7).

*Induced proteosomal degradation of HDAC-2 protein*

Altered protein levels in the absence of alterations in steady state mRNA levels strongly suggest an effect on the rate of protein synthesis or protein degradation. HDAC-2 protein synthesis rate with and without VPA pretreatment (24 h) was compared by pulse labeling with <sup>35</sup>S-methionine in F9 or HEK293T cells. No substantial difference in HDAC-2 synthesis rate between control or VPA treated cells was found (Figure 8A).

Protein half-life times were determined by a pulse-chase analysis, both, in F9 and HEK293T cells. The half-life of HDAC-2 was substantially decreased by pretreatment of cells with VPA (Figure 8B). VPA had no effect on HDAC-2 protein degradation rate when added only at the time of chase (panel marked by (+) in Figure 8B) providing a further indication that the response of HDAC-2 protein levels to VPA is indirect rather than being a direct response, e.g. to a conformational change of HDAC-2. Degradation of HDAC-3 was not affected by VPA pretreatment of HEK293T cells (Figure 8B) consistent with a lack of reduction in steady state HDAC-3 protein levels upon VPA treatment.

To discriminate whether HDAC-2 degradation could be due to either protease-dependent or proteosomal degradation several inhibitors of proteases (Figure 9A) or the proteasome (Figure 9B) were applied in combination with VPA. Neither of the protease inhibitors pepstatin A, leupeptin or ALLM had an effect on control or VPA-repressed HDAC-2 protein levels (Figure 9A). Co-treatment of HEK293T cells with the proteasome inhibitors ALLN or MG-132 abolished VPA-induced degradation of HDAC-2 completely (Figure 9B). Thus, increased proteosomal degradation by an indirect mechanism involving synthesis of intermediary factors appears to be the most likely mechanism of VPA induced degradation of HDAC-2 protein.

A prerequisite of proteosomal degradation is the 'tagging' of the substrate protein for recognition by the proteasome. The most common mechanism of proteosomal targeting depends on poly-ubiquitination and, therefore, presence and VPA-dependent induction of



ubiquitinated HDAC-2 was tested. First, immune precipitates prepared with an antibody directed against HDAC-2 were analyzed by Westernblot against ubiquitin for the presence of high molecular weight ubiquitinated proteins. Untreated cells contain a small amount of ubiquitin containing proteins that precipitate with an antibody against HDAC-2 (Figure 10A). Pretreatment of cells with either the proteasome inhibitor ALLN to prevent degradation of ubiquitinated proteins or with VPA increase the amount of this anti-ubiquitin reactive protein. Cotreatment with VPA and ALLN even further increases the amount of high molecular weight ubiquitinated proteins. The overall amount of cellular ubiquitinated proteins is, in contrast, moderately reduced by VPA treatment. TSA has no effect on the amount of immune precipitated anti-ubiquitin-reactive material. These data suggest that VPA-treatment induces ubiquitination of (a) protein(s) that precipitate with an antibody against HDAC-2.

The latter type of assay aiming at detecting the ubiquitinated forms of HDAC-2 was further improved by transient expression of His<sub>6</sub>-tagged ubiquitin and using Ni<sup>2+</sup>-NTA agarose for precipitation (Figure 10B). Expression of recombinant ubiquitin does not substantially affect the total cellular amounts of HDAC-2 and, if present at all, ubiquitinated forms of HDAC-2 are below the detection limits of Westernblot analysis from whole cell extracts (left panel). Ni<sup>2+</sup>-NTA-agarose precipitates contain ubiquitinated proteins over almost the whole range of resolved protein sizes when Westernblots are probed with an anti His-tag antibody (right panel). Detection of ubiquitinated proteins is specific since no signal is seen if cells are not transfected to express the tagged ubiquitin. Gross abundance of ubiquitinated proteins is not altered by VPA treatment of cells. The prominent band at about 60 kDa most likely represents the ubiquitin concatamer encoded by the expression vector. If probed for presence of HDAC-2 the Ni<sup>2+</sup>-NTA-agarose precipitates clearly show the presence of oligo- and polyubiquitinated HDAC-2 (middle panel). The prominent band migrating between 64 and 81 kDa most likely represents mono-ubiquitinated HDAC-2 and a ladder of bands consistent with the expected mobility of any degree of HDAC-2 ubiquitination up to high molecular weight polyubiquitination is found. These bands are visible at low abundance in precipitates from untreated cells and are much more abundant if cells are pretreated with VPA. The detection is specific for ubiquitinated HDAC-2 since no such bands are visible if the cells do not express His-tagged ubiquitin. HDAC-2 specificity is established by the use of the proper antibody. The band comigrating with HDAC-2 just below 64 kDa most likely corresponds to unmodified HDAC-2 which could well be coprecipitated in larger corepressor complexes that contain several HDAC-2

molecules of which not all would have to be ubiquitinated. In summary, this part of the data shows that HDAC-2 can be ubiquitinated and degraded by the proteasome by a mechanism inducible by VPA but not by TSA.

### **EXAMPLE 3**

Valproic acid defines a class of HDAC inhibitors that induce expression of the E2 ubiquitin conjugating enzyme Ubc8, leading to ubiquitination of HDAC's 1-3 by the E3 ubiquitin ligase, RLIM (Figure 11-13).

Degradation of a protein via the ubiquitin pathway involves two successive steps: (1) tagging of the substrate by covalent attachment of multiple ubiquitin molecules, and (2) degradation of the tagged protein by the 26S proteasome complex with release of free and reusable ubiquitin.

The 26S proteasome is the key enzyme complex of the ubiquitin/ATP-dependent pathway of protein degradation. The 26S complex binds ATP and is responsible for the degradation of proteins that have been targeted for degradation by conjugation with ubiquitin. Ubiquitin is attached to a target protein by an isopeptide bond formed between the epsilon-amino group of lysine on the target and the C-terminal glycine residue of ubiquitin by a series of ubiquitin conjugating enzymes, E1, E2 and E3. Ubiquitin conjugating enzymes act in series by transferring a ubiquitin chain from one enzyme to the next, followed by the transfer of the activated ubiquitin chain from the E2 enzyme to the target protein. The mono-ubiquitinated protein is then acted upon again and the same enzymes attach an additional ubiquitin molecule to the previous one. Ubiquitin conjugation continues resulting in a high molecular weight protein complex. This poly-ubiquitinated product then becomes the target for rapid degradation by the 26S proteasome with concomitant recycling of ubiquitin catalysed by the isopeptidases (Ciechanover and Schwartz, 2002, *Hepatology* 35: 3-6).

The present invention demonstrates the ability of certain HDAC inhibitors, namely valproic acid, to selectively induce expression of the E2 ubiquitin conjugating enzyme Ubc8, without changing expression of the E3 ubiquitin ligase, RLIM. This induction of Ubc8 enhances ubiquitination of RLIM associated proteins, such as HDAC-2. On the other hand, some HDAC inhibitors (e. g. TSA) induce an enhanced proteosomal degradation of the E3

ligase RLIM, which consequently becomes the limiting factor for HDAC-2 turnover. These observations provide a plausible explanation for the differential effects on HDAC-2 protein levels observed upon treatment with different HDAC inhibitors.

## METHODS

**Figure 11** (A) F9 cells were treated for indicated times with 1 mM VPA and abundance of Ubc8 mRNA was determined by Northern blot analysis from 5  $\mu$ g polyA<sup>+</sup> mRNA with a probe derived from the 3'-UTR of the cDNA. GAPDH mRNA was determined as reference. Phosphorimager analysis was performed for quantitative evaluation and relative values normalized for GAPDH are presented below the graph. One of two experiments with similar results is shown. (B) Ubc8 mRNA was also determined by real time PCR assuming an 1.5-fold amplification per cycle. The amplicon was part of the coding sequence of the Ubc8 mRNA. F9 cells were treated for 17 h with 1 mM VPA (V) or 100 nM TSA (T). Results were normalized for GAPDH expression. Average values  $\pm$  range of duplicate determinations are shown.

**Figure 12** (A) RLIM protein levels were determined by Westernblot analysis after treatment of HEK293T cells for 24 hours with the HDAC inhibitors VPA (0.5, 1.5, or 5 mM), TSA (30, 100 or 300 nM) or a combination of VPA (1.5 mM) and TSA (100 nM). Actin protein levels are shown as a control for equal loading. (B) RLIM protein levels were determined by Westernblot analysis after treatment of HEK293T cells for 24 hours with the HDAC inhibitor TSA (100 nM), the proteasome inhibitor ALLN (2.5  $\mu$ M) or a combination of both. Actin protein levels are shown as a control for equal loading.

**Figure 13:** In vitro translated <sup>35</sup>S-methionine labeled HDACs 1-3 were incubated for 2 h in buffer with E1 ubiquitin ligase and ubiquitin only, or in reactions containing the recombinantly expressed E2 ubiquitin ligase Ubc8 without or together with the E3 ligase RLIM. For control (left lanes) reactions were stopped immediately after addition of ubiquitin and E1 ligase. Loss of input HDAC and appearance of high molecular weight radioactively labeled protein were determined by SDS PAGE followed by autoradiography.

## RESULTS

### *Identification of ubiquitin ligases for HDAC's 1-3*

Proteins of the ubiquitination machinery that can mediate HDAC-2 degradation were identified by two approaches. A systematic search for VPA inducible genes in F9 cells had revealed that expression of the gene encoding the E2 conjugating enzyme Ubc8 is inducible by VPA (Figure 11). Association of RLIM with the mSin3 corepressor (Ostendorff et al., 2002, Nature 416:99-103) had identified this E3 ubiquitin ligase as a prime candidate to be active also towards other components of corepressor complexes, e.g. HDACs. Interestingly, Ubc8 serves as E2 conjugating enzyme for RLIM ligase so that both proteins act synergistically .

In contrast to VPA, some HDAC inhibitors such as TSA induce an enhanced proteasomal degradation of the E3 ligase RLIM, which can be blocked with the 26S proteasome inhibitor ALLN (Fig. 12). Consequently, RLIM becomes the limiting factor for HDAC-2 turnover in the presence of TSA. Therefore, differential effects on HDAC-2 protein levels are observed upon treatment with different HDAC inhibitors.

In vitro ubiquitination assays with Ubc8 as E2 and RLIM as E3 ubiquitin ligases demonstrated that several class I HDACs, e.g. HDACs 1-3 (Figure 13), and the class II HDAC-4 are substrates for Ubc8/ RLIM. Both, the disappearance of the non-modified in vitro translated HDAC as well as the appearance of slower migrating proteins of the expected mobility of mono-, oligo-, and poly-ubiquitinated HDACs could be observed. Efficient ubiquitination was only found, if both recombinantly expressed proteins, Ubc8 and RLIM, were included in the reactions but not if only ubiquitin and an E1 ligase were present. In the case of HDAC-2 disappearance of unmodified protein and appearance of slowly migrating poly-ubiquitinated forms was most pronounced. Formation of ladders presumably representing various degrees of mono- and oligo-ubiquitination was observed better in the case of HDAC-1. In either case the data clearly show that Ubc8 and RLIM can ubiquitinate HDACs 1, 2, and 3 in cell free *in vitro* reactions.

**EXAMPLE 4**

HDAC-2 is overexpressed in human colon cancer (Figure 14, Table 1)

Cancer of the colon is the second most frequently diagnosed malignancy in the United States as well as the second most common cause of cancer death. Surgery is the primary treatment and results in cure in approximately 50% of patients. Recurrence following surgery is a major problem and often is the ultimate cause of death. Elevated pretreatment serum levels of carcinoembryonic antigen (CEA) have a negative prognostic significance. Here we present evidence that HDAC-2 is overexpressed in over 80% of colon cancer probes investigated so far.

One aspect of the present invention is the use of HDAC-2 expression as a molecular marker to identify patients and tumor entities that may respond to a therapy with HDAC inhibitors. Furthermore, HDAC-2 expression in tumor cells can be used to monitor efficacy of HDAC inhibitor treatment in patients.

**METHODS**

**Figure 14:** Paraffin colon cancer and matched normal tissue arrays (Biocat, Heidelberg) were deparaffinized with two changes of Xylene and a descending ethanol gradient (ethanol concentration: 100% 2x 5min.; 95% 3 min.; 70% 3min.) and were washed in PBS. Blocking was done in 10 % normal goat serum (DAKO Diagnostika, Hamburg) in PBS for 15 min. Incubation with 10 $\mu$ g/ml in 10%FCS/PBS of the HDAC-2-rabbit polyclonal antibody (Zymed, San Francisco) was done for one hour. After washing the slides 3x in PBS the sections were incubated with Cy3 coupled goat  $\alpha$ -rabbit IgG F(ab')<sub>2</sub>-Fragments (1:500 in 10% FCS/PBS) (Dianova, Hamburg) for 30 min. After the final washings in PBS (3x) the sections were covered with a coverslip. All photographs were taken with a Zeiss LSM 510 laserscanning inverted confocal microscope with the appropriate filters for Cy3.

**RESULTS**

To investigate HDAC-2 expression in human tissue, biopsies from 46 colon cancer patients containing both tumor tissue and normal colon tissue from each patient were stained with an antibody against human HDAC-2 and a secondary antibody for immunofluorescence. As can be seen in Figure 14, very little staining for HDAC-2

expression could be detected in normal tissue, however over 80% of biopsies from tumor tissue displayed strong expression of HDAC-2 (Figure 14 and Table 1). This indicates that HDAC-2 over-expression is a very common feature in colon cancer and may be used as a prognostic and diagnostic marker in colon cancer patients. Furthermore, these results raise the hope that colon cancer patients benefit from a treatment that aims to reduce HDAC-2 expression in tumor tissue.

TABLE 1: Results from Immunofluorescence Detection of HDAC-2 Expression in Tumor Biopsies from Colon Cancer Patients (Compared to Matched Normal Tissue)

	Normal HDAC-2 expression	HDAC-2 overexpressed	total
# samples	8	38	46
% samples	17	83	100

## Claims

1. A method for the characterization of an HDAC inhibitor or a potential HDAC inhibitor comprising  
determining in a sample the amount of a molecular marker  
wherein the sample is derived from cells which have been treated with said HDAC inhibitor or potential HDAC inhibitor.
2. A method according to claim 1 wherein the molecular marker is selected from the group consisting of HDAC-2 RNA, HDAC-2 protein, Ubc8 RNA, UBC8 protein, RLIM RNA, RLIM protein, TRAIL RNA and TRAIL protein.
3. A method according to claim 1 or 2 wherein the sample is derived from tissue affected by a disorder.
4. A method according to claim 3 wherein the disorder is selected from but not restricted to the group consisting of skin cancer, melanoma, estrogen receptor-dependent and independent breast cancer, ovarian cancer, prostate cancer, renal cancer, colon and colorectal cancer, pancreatic cancer, head and neck cancer, small cell and non-small cell lung carcinoma, leukemias and other types of blood cell cancer and endocrine disease based on aberrant recruitment of histone deacetylase such as thyroid resistance syndrome.
5. A method according to anyone of claims 1 to 4 wherein the molecular marker is a ribonucleic acid and the amount of the molecular marker is determined by RT-PCR.
6. A method according to anyone of claims 1 to 4 wherein the molecular marker is a protein and the amount of the molecular marker is determined by use of an antibody directed against the molecular marker.
7. A method according to claim 6 wherein the amount of molecular marker is determined by Western Blotting, ELISA, immunohistochemistry and/or flow cytometry.
8. A method according to anyone of claims 1 to 7 further comprising the step of selecting the inhibitor if it has the activity of modulating the expression of the molecular marker.

9. A method according to anyone of claims 1 to 8 further comprising the step of determining in a reference sample the amount of said molecular marker wherein the reference sample is derived from cells which have not been treated with said HDAC inhibitor or potential HDAC inhibitor.
10. The use of a means for determining the amount of a molecular marker for profiling of HDAC inhibitors or potential HDAC inhibitors.
11. The use of a means for determining the amount of a molecular marker for diagnosing a disease.
12. The use of a means for determining the amount of a molecular marker for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not.
13. The use of a means for determining the amount of a molecular marker for determining whether a treatment of a disorder with a therapy that targets a molecular marker is to be started/continued or not.
14. The use according to any one of claims 10 to 13 wherein the means for determining the amount of a molecular marker is an antibody directed against a protein selected from the group consisting of HDAC-2 protein, UBC8 protein, RLIM protein and TRAIL protein.
15. The use according to any one of claims 10 to 13 wherein the means for determining the amount of a molecular marker is an oligonucleotide capable of hybridizing to a polynucleotide selected from the group consisting of RLIM mRNA, RLIM cDNA, Ubc8 mRNA, Ubc8 cDNA, TRAIL mRNA, TRAIL cDNA, HDAC-2 mRNA, HDAC-2 cDNA and complements thereof.
16. The use according to claim 15 wherein the oligonucleotide is used as a primer in a polymerase chain reaction or in a RT-PCR.



17. The use according to claim 15 wherein the oligonucleotide is used as a probe in a hybridization reaction.
18. A diagnostic kit containing
  - (i) means for determining the amount of a molecular marker and
  - (ii) an HDAC inhibitor.
19. A diagnostic kit according to claim 18 wherein the means for determining the amount of a molecular marker is an antibody directed against a protein selected from the group consisting of HDAC-2 protein, UBC8 protein, RLIM protein and TRAIL protein.
20. A diagnostic kit according to claim 18 wherein the means for determining the amount of a molecular marker is an oligonucleotide capable of hybridizing to a polynucleotide selected from the group consisting of RLIM mRNA, RLIM cDNA, Ubc8 mRNA, Ubc8 cDNA, TRAIL mRNA, TRAIL cDNA, HDAC-2 mRNA, HDAC-2 cDNA and complements thereof.

Figure 1






Figure 2


A



H3

B

Ctr



VPA





Figure 3

A



B





Figure 4 **A**



**B**






Figure 5




6/14

Figure 6



7/14


Figure 7







8/14

Figure 8




9/14

Figure 9



10/14


Figure 10




11/14

Figure 11

A




B



12/14

Figure 12

A



B




Figure 13





Figure 14



1  
SEQUENCE LISTING

<110> G2M Cancer Drugs AG

Forschungszentrum Karlsruhe GmbH

<120> The use of molecular markers for the preclinical and clinical  
profiling of inhibitors of enzymes having histone deacetylase activity

<130> molecular markers

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 488

<212> PRT

<213> homo sapiens

<400> 1

Met Ala Tyr Ser Gln Gly Gly Gly Lys Lys Lys Val Cys Tyr Tyr Tyr  
1 5 10 15

Asp Gly Asp Ile Gly Asn Tyr Tyr Tyr Gly Gln Gly His Pro Met Lys  
20 25 30

Pro His Arg Ile Arg Met Thr His Asn Leu Leu Leu Asn Tyr Gly Leu  
35 40 45

Tyr Arg Lys Met Glu Ile Tyr Arg Pro His Lys Ala Thr Ala Glu Glu  
50 55 60

Met Thr Lys Tyr His Ser Asp Glu Tyr Ile Lys Phe Leu Arg Ser Ile  
65 70 75 80

Arg Pro Asp Asn Met Ser Glu Tyr Ser Lys Gln Met His Ile Phe Asn  
85 90 95

Val Gly Glu Asp Cys Pro Ala Phe Asp Gly Leu Phe Glu Phe Cys Gln  
100 105 110

Leu Ser Thr Gly Gly Ser Val Ala Gly Ala Val Lys Leu Asn Arg Gln  
115 120 125



Gln Thr Asp Met Ala Val Asn Trp Ala Gly Gly Leu His His Ala Lys  
 130 135 140  
 Lys Tyr Glu Ala Ser Gly Phe Cys Tyr Val Asn Asp Ile Val Leu Ala  
 145 150 155 160  
 Ile Leu Glu Leu Leu Lys Tyr His Gln Arg Val Leu Tyr Ile Asp Ile  
 165 170 175  
 Asp Ile His His Gly Asp Gly Val Glu Glu Ala Phe Tyr Thr Thr Asp  
 180 185 190  
 Arg Val Met Thr Val Ser Phe His Lys Tyr Gly Glu Tyr Phe Pro Gly  
 195 200 205  
 Thr Gly Asp Leu Arg Asp Ile Gly Ala Gly Lys Gly Lys Tyr Tyr Ala  
 210 215 220  
 Val Asn Phe Pro Met Cys Asp Gly Ile Asp Asp Glu Ser Tyr Gly Gln  
 225 230 235 240  
 Ile Phe Lys Pro Ile Ile Ser Lys Val Met Glu Met Tyr Gln Pro Ser  
 245 250 255  
 Ala Val Val Leu Gln Cys Gly Ala Asp Ser Leu Ser Gly Asp Arg Leu  
 260 265 270  
 Gly Cys Phe Asn Leu Thr Val Lys Gly His Ala Lys Cys Val Glu Val  
 275 280 285  
 Val Lys Thr Phe Asn Leu Pro Leu Leu Met Leu Gly Gly Gly Tyr  
 290 295 300  
 Thr Ile Arg Asn Val Ala Arg Cys Trp Thr Tyr Glu Thr Ala Val Ala  
 305 310 315 320  
 Leu Asp Cys Glu Ile Pro Asn Glu Leu Pro Tyr Asn Asp Tyr Phe Glu  
 325 330 335  
 Tyr Phe Gly Pro Asp Phe Lys Leu His Ile Ser Pro Ser Asn Met Thr  
 340 345 350  
 Asn Gln Asn Thr Pro Glu Tyr Met Glu Lys Ile Lys Gln Arg Leu Phe  
 355 360 365  
 Glu Asn Leu Arg Met Leu Pro His Ala Pro Gly Val Gln Met Gln Ala  
 370 375 380  
 Ile Pro Glu Asp Ala Val His Glu Asp Ser Gly Asp Glu Asp Gly Glu  
 385 390 395 400

3

Asp Pro Asp Lys Arg Ile Ser Ile Arg Ala Ser Asp Lys Arg Ile Ala  
 405 410 415

Cys Asp Glu Glu Phe Ser Asp Ser Glu Asp Glu Gly Glu Gly Gly Arg  
 420 425 430

Arg Asn Val Ala Asp His Lys Lys Gly Ala Lys Lys Ala Arg Ile Glu  
 435 440 445

Glu Asp Lys Lys Glu Thr Glu Asp Lys Lys Thr Asp Val Lys Glu Glu  
 450 455 460

Asp Lys Ser Lys Asp Asn Ser Gly Glu Lys Thr Asp Thr Lys Gly Thr  
 465 470 475 480

Lys Ser Glu Gln Leu Ser Asn Pro  
 485

<210> 2

<211> 183

<212> PRT

<213> homo sapiens

<400> 2

Met Ser Ser Pro Ser Pro Gly Lys Arg Arg Met Asp Thr Asp Val Val  
 1 5 10 15

Lys Leu Ile Glu Ser Lys His Glu Val Thr Ile Leu Gly Gly Leu Asn  
 20 25 30

Glu Phe Val Val Lys Phe Tyr Gly Pro Gln Gly Thr Pro Tyr Glu Gly  
 35 40 45

Gly Val Trp Lys Val Arg Val Asp Leu Pro Asp Lys Tyr Pro Phe Lys  
 50 55 60

Ser Pro Ser Ile Gly Phe Met Asn Lys Ile Phe His Pro Asn Ile Asp  
 65 70 75 80

Glu Ala Ser Gly Thr Val Cys Leu Asp Val Ile Asn Gln Thr Trp Thr  
 85 90 95

Ala Leu Tyr Asp Leu Thr Asn Ile Phe Glu Ser Phe Leu Pro Gln Leu  
 100 105 110

Leu Ala Tyr Pro Asn Pro Ile Asp Pro Leu Asn Gly Asp Ala Ala Ala  
 115 120 125

Met Tyr Leu His Arg Pro Glu Glu Tyr Lys<sup>4</sup> Gln Lys Ile Lys Glu Tyr  
 130 135 140

Ile Gln Lys Tyr Ala Thr Glu Glu Ala Leu Lys Glu Gln Glu Glu Gly  
 145 150 155 160

Thr Gly Asp Ser Ser Ser Glu Ser Ser Met Ser Asp Phe Ser Glu Asp  
 165 170 175

Glu Ala Gln Asp Met Glu Leu  
 180

<210> 3

<211> 624

<212> PRT

<213> homo sapiens

<400> 3

Met Glu Asn Ser Asp Ser Asn Asp Lys Gly Ser Gly Asp Gln Ser Ala  
 1 5 10 15

Ala Gln Arg Arg Ser Gln Met Asp Arg Leu Asp Arg Glu Glu Ala Phe  
 20 25 30

Tyr Gln Phe Val Asn Asn Leu Ser Glu Glu Asp Tyr Arg Leu Met Arg  
 35 40 45

Asp Asn Asn Leu Leu Gly Thr Pro Gly Glu Ser Thr Glu Glu Glu Leu  
 50 55 60

Leu Arg Arg Leu Gln Gln Ile Lys Glu Gly Pro Pro Pro Gln Asn Ser  
 65 70 75 80

Asp Glu Asn Arg Gly Gly Asp Ser Ser Asp Asp Val Ser Asn Gly Asp  
 85 90 95

Ser Ile Ile Asp Trp Leu Asn Ser Val Arg Gln Thr Gly Asn Thr Thr  
 100 105 110

Arg Ser Gly Gln Arg Gly Asn Gln Ser Trp Arg Ala Val Cys Arg Thr  
 115 120 125

Asn Pro Asn Ser Gly Asn Phe Arg Phe Ser Leu Glu Ile Asn Val Tyr  
 130 135 140

Ser Asn Asn Gly Ser Gln Asn Ser Glu Asn Glu Asn Glu Pro Ser Ala  
 145 150 155 160

Arg Arg Ser Ser Gly Glu Asn Val Glu Asn Asn Ser Gln Arg Gln Val

										5									
165					170					175									
Glu	Asn	Pro	Arg	Ser	Glu	Ser	Thr	Ser	Ala	Arg	Pro	Ser	Arg	Ser	Glu				
			180					185					190						
Arg	Asn	Ser	Thr	Glu	Ala	Leu	Thr	Glu	Val	Pro	Pro	Thr	Arg	Gly	Gln				
		195					200						205						
Arg	Arg	Ala	Arg	Ser	Arg	Ser	Pro	Asp	His	Arg	Arg	Thr	Arg	Ala	Arg				
	210					215					220								
Ala	Glu	Arg	Ser	Arg	Ser	Pro	Leu	His	Pro	Met	Ser	Glu	Ile	Pro	Arg				
225					230					235					240				
Arg	Ser	His	His	Ser	Ile	Ser	Ser	Gln	Thr	Phe	Glu	His	Pro	Leu	Val				
				245					250					255					
Asn	Glu	Thr	Glu	Gly	Ser	Ser	Arg	Thr	Arg	His	His	Val	Thr	Leu	Arg				
			260					265					270						
Gln	Gln	Ile	Ser	Gly	Pro	Glu	Leu	Leu	Ser	Arg	Gly	Leu	Phe	Ala	Ala				
		275					280					285							
Ser	Gly	Thr	Arg	Asn	Ala	Ser	Gln	Gly	Ala	Gly	Ser	Ser	Asp	Thr	Ala				
	290					295					300								
Ala	Ser	Gly	Glu	Ser	Thr	Gly	Ser	Gly	Gln	Arg	Pro	Pro	Thr	Ile	Val				
305					310					315					320				
Leu	Asp	Leu	Gln	Val	Arg	Arg	Val	Arg	Pro	Gly	Glu	Tyr	Arg	Gln	Arg				
				325					330					335					
Asp	Ser	Ile	Ala	Ser	Arg	Thr	Arg	Ser	Arg	Ser	Gln	Thr	Pro	Asn	Asn				
			340					345					350						
Thr	Val	Thr	Tyr	Glu	Ser	Glu	Arg	Gly	Gly	Phe	Arg	Arg	Thr	Phe	Ser				
		355					360					365							
Arg	Ser	Glu	Arg	Ala	Gly	Val	Arg	Thr	Tyr	Val	Ser	Thr	Ile	Arg	Ile				
		370				375					380								
Pro	Ile	Arg	Arg	Ile	Leu	Asn	Thr	Gly	Leu	Ser	Glu	Thr	Thr	Ser	Val				
385					390					395					400				
Ala	Ile	Gln	Thr	Met	Leu	Arg	Gln	Ile	Met	Thr	Gly	Phe	Gly	Glu	Leu				
				405					410					415					
Ser	Tyr	Phe	Met	Tyr	Ser	Asp	Ser	Asp	Ser	Glu	Pro	Thr	Gly	Ser	Val				
			420					425					430						
Ser	Asn	Arg	Asn	Met	Glu	Arg	Ala	Glu	Ser	Arg	Ser	Gly	Arg	Gly	Gly				
		435					440					445							

Ser Gly Gly Gly Ser Ser Ser Gly Ser Ser Ser Ser Ser Ser Ser  
 450 455 460

Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Pro Ser Ser Ser  
 465 470 475 480

Ser Gly Gly Glu Ser Ser Glu Thr Ser Ser Asp Leu Phe Glu Gly Ser  
 485 490 495

Asn Glu Gly Ser Ser Ser Ser Gly Ser Ser Gly Ala Arg Arg Glu Gly  
 500 505 510

Arg His Arg Ala Pro Val Thr Phe Asp Glu Ser Gly Ser Leu Pro Phe  
 515 520 525

Leu Ser Leu Ala Gln Phe Phe Leu Leu Asn Glu Asp Asp Asp Asp Gln  
 530 535 540

Pro Arg Gly Leu Thr Lys Glu Gln Ile Asp Asn Leu Ala Met Arg Ser  
 545 550 555 560

Phe Gly Glu Asn Asp Ala Leu Lys Thr Cys Ser Val Cys Ile Thr Glu  
 565 570 575

Tyr Thr Glu Gly Asn Lys Leu Arg Lys Leu Pro Cys Ser His Glu Tyr  
 580 585 590

His Val His Cys Ile Asp Arg Trp Leu Ser Glu Asn Ser Thr Cys Pro  
 595 600 605

Ile Cys Arg Arg Ala Val Leu Ala Ser Gly Asn Arg Glu Ser Val Val  
 610 615 620

<210> 4

<211> 281

<212> PRT

<213> homo sapiens

<400> 4

Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys  
 1 5 10 15

Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala  
 20 25 30

Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys  
 35 40 45

7

Tyr Ser Lys Ser Gly Ile Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr  
 50 55 60

Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val  
 65 70 75 80

Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser  
 85 90 95

Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro  
 100 105 110

Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly  
 115 120 125

Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu  
 130 135 140

Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly  
 145 150 155 160

His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile  
 165 170 175

His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe  
 180 185 190

Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln  
 195 200 205

Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys  
 210 215 220

Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr  
 225 230 235 240

Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile  
 245 250 255

Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala  
 260 265 270

Ser Phe Phe Gly Ala Phe Leu Val Gly  
 275 280

<210> 5

<211> 1985

<212> DNA

<213> homo sapiens

<400> 5  
cgccgagctt tcggcacctc tgccgggtgg taccgagcct tcccggcgcc cctcctctc 60  
ctcccaccgg cctgcccttc cccgcgggac tatcgcccc acgtttccct cagccctttt 120  
ctctcccggc cgagccgcgg cggcagcagc agcagcagca gcagcaggag gaggagcccg 180  
gtggcggcgg tggccgggga gcccatggcg tacagtcaag gaggcggcaa aaaaaaagtc 240  
tgctactact acgacggtga tattggaaat tattattatg gacagggta tcccatgaag 300  
cctcatagaa tccgcatgac ccataacttg ctgttaaatt atggcttata cagaaaaatg 360  
gaaatatata ggccccataa agccactgcc gaagaaatga caaaatatca cagtgatgag 420  
tatatcaaat ttctacggtc aataagacca gataacatgt ctgagtatag taagcagatg 480  
catatattta atgttggaag agattgtcca gcgtttgatg gactctttga gttttgtcag 540  
ctctcaactg gcggttcagt tgctggagct gtgaagttaa accgacaaca gactgatatg 600  
gctgttaatt gggctggagg attacatcat gctaagaaat acgaagcatc aggattctgt 660  
tacgttaatg atattgtgct tgccatcctt gaattactaa agtatcatca gagagtctta 720  
tatattgata tagatattca tcatggtgat ggtgttgaag aagcttttta tacaacagat 780  
cgtgtaatga cggatcatt ccataaatat ggggaatact ttcctggcac aggagacttg 840  
agggatattg gtgctggaaa agggcaaac tatgctgtca attttccaat gtgtgatggt 900  
atagatgatg agtcatatgg gcagatattt aagcctatta tctcaaagg gatggagatg 960  
tatcaacctg gtgctgtggt attacagtgt ggtgcagact cattatctgg tgatagactg 1020  
ggttgtttca atctaacagt caaaggatcat gctaaatgtg tagaagttgt aaaaactttt 1080  
aacttaccat tactgatgct tggaggagggt ggctacacaa tccgtaatgt tgctcgatgt 1140  
tggacatatg agactgcagt tgcccttgat tgtgagattc ccaatgagtt gccatataat 1200  
gattactttg agtatttttg accagacttc aaactgcata ttagtccttc aaacatgaca 1260  
aaccagaaca ctccagaata tatggaaaag ataaaacagc gtttgtttga aaatttgcgc 1320  
atgttacctc atgcacctgg tgtccagatg caagctattc cagaagatgc tgttcatgaa 1380  
gacagtggag atgaagatgg agaagatcca gacaagagaa tttctattcg agcatcagac 1440  
aagcggatag cttgtgatga agaattctca gattctgagg atgaaggaga aggaggtcga 1500  
agaaatgtgg ctgatcataa gaaaggagca aagaaagcta gaattgaaga agataagaaa 1560  
gaaacagagg acaaaaaaac agacgttaag gaagaagata aatccaagga caacagtgggt 1620  
gaaaaaacag ataccaaagg aaccaaatca gaacagctca gcaaccctg aatttgacag 1680  
tctcaccaat ttcagaaaat cattaaaaag aaaatattga aaggaaaaatg ttttcttttt 1740  
gaagacttct ggcttcattt tatactactt tggcatggac tgtatttatt ttcaaatggg 1800  
actttttcgt ttttgttttt ctgggcaagt tttattgtga gattttctaa ttatgaagca 1860  
aaatttcttt tctccaccat gctttatgtg atagtattta aaattgatgt gagttattat 1920  
gtcaaaaaaa ctgatctatt aaagaagtaa ttggcctttc tgagctgaaa aaaaaaaaaa 1980

aaaag

1985

&lt;210&gt; 6

&lt;211&gt; 761

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 6

ccgggccgtg acagacggcc ggcagaggaa gggagagagg cggcggcgac accatgtcat	60
ctcccagttcc gggcaagagg cggatggaca cggacgtggt caagctcatc gagagtaaac	120
atgaggttac gatcctggga ggacttaatg aatttgtagt gaagttttat ggaccacaag	180
gaacaccata tgaaggcgga gtatggaaag ttagagtggga cctacctgat aaataccctt	240
tcaaatctcc atctatagga ttcatgaata aaattttcca tcccaacatt gatgaagcgt	300
caggaactgt gtgtctagat gtaattaatc aaacttggac agctctctat gatcttacca	360
atatatttga gtccttcctg cctcagttat tggcctatcc taaccccata gatcctctca	420
atggtgacgc tgcagccatg tacctccacc gaccagaaga atacaagcag aaaattaaag	480
agtacatcca gaaatacgcc acggaggagg cgctgaaaga acaggaagag ggtaccgggg	540
acagctcatc ggagagctct atgtctgact tttccgaaga tgaggcccaag gatatggagt	600
tgtagtagaa aaagcacctg cttttcagaa agactattat ttcctaacca tgagaagcag	660
actataatat tcatatttaa acaaagcaat tttttttatt actaaacaag gtttttatga	720
ataatagcat tgatatatat atattatata tcacccttta g	761

&lt;210&gt; 7

&lt;211&gt; 1875

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 7

atggaaaact cagattccaa tgacaaagga agtggatgac agtctgcagc acagcgcaga	60
agtcagatgg accgattgga tcgagaagaa gctttctatc aatttgtaaa taacctgagt	120
gaagaagatt ataggcttat gagagataac aatttgctag gcaccccagg tgaaagtact	180
gaggaagagt tgctgagacg actacagcaa attaaagaag gccaccacc gcaaaactca	240
gatgaaaata gaggaggaga ctcttcagat gatgtgtcta atggtgactc tataatagac	300
tggcttaact ctgtcagaca aactggaaat acaacaagaa gtgggcaaag aggaaaccaa	360
tcttggagag cagtgtgccg gactaatcca aacagcggta atttcagatt cagtttagag	420
ataaatgttt acagtaataa tgggagccaa aattcagaga atgaaaatga gccatctgca	480
agacgttcta gtggagaaaa tgtggaaaac aacagccaaa ggcaagtgga aaaccacga	540



tctgaatcaa catctgcaag gccatctaga tcagaacgaa attcaactga agcggttaaca	600
gagggtccac ctaccagagg tcagaggagg gcaagaagca ggagcccaga ccatcggaga	660
accagagcaa gagctgaaag aagtaggtca cctctgcatc caatgagtga aattccacga	720
agatctcatc atagtatctc atctcagact tttgaacatc ctttggtaaa tgagacggag	780
ggaagttcta gaacccggca ccatgtgaca ttgaggcagc aaatatctgg gcctgagttg	840
ctaagtagag gtctttttgc agcttctgga acaagaaatg cttctcaagg agcaggttct	900
tcagacacag ctgccagtgg tgaatctaca ggatcaggac agagacctcc aaccatagtc	960
cttgatcttc aagtaagaag agttcgtcct ggagaatatc ggcagagaga tagcatagcc	1020
agcagaactc ggtctaggtc tcagacacca aacaacactg tcacctatga aagtgaacga	1080
ggaggtttta ggcgtacatt ttcacgttct gagcgggcag gtgtgagaac ctatgtcagt	1140
accatcagaa ttcccattcg tagaatctta aatactgggt taagtgagac tacatctgtt	1200
gcaattcaga ccatgttaag gcagataatg acaggttttg gtgagttaag ctattttatg	1260
tacagtgata gcgactcaga gcctactggc tcagtctcaa atcgaaatat ggaaagggca	1320
gagtcacgga gtggaagagg aggttctggt ggtggtagta gttctggtc cagttcgagt	1380
tccagttcca gttcgagttc cagttccagt tcaagttcca gttccagtcc tagttccagt	1440
tccggtggtg aaagttcaga aactagctca gatttatttg aaggcagtaa tgaaggaagc	1500
tcatcatcag gctcatcagg tgccaggcga gagggctgac atagggcccc agtcacattt	1560
gatgaaagtg gctctttgcc cttccttagc ctggctcagt ttttcctctt aaatgaggat	1620
gatgatgacc aacctagagg actcacaaa gaacagattg acaacttggc aatgagaagt	1680
tttggtgaaa atgatgcatt aaaaacctgt agtgtttgca ttacagaata tacagaaggc	1740
aacaaacttc gtaaaactacc ttgttcccat gagtaccatg tccactgcat cgatcgctgg	1800
ttatctgaga attctacctg tcctatttgt cgcagagcag tcttagcttc tggtaacaga	1860
gaaagtgttg tgtaa	1875

&lt;210&gt; 8

&lt;211&gt; 1769

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 8

cctcactgac tataaaagaa tagagaagga agggcttcag tgaccggctg cctggctgac	60
ttacagcagt cagactctga caggatcatg gctatgatgg aggtccaggg gggacccagc	120
ctgggacaga cctgctgtct gatcgtgatc ttcacagtgc tcctgcagtc tctctgtgtg	180
gctgtaactt acgtgtactt taccaacgag ctgaagcaga tgcaggacaa gtactccaaa	240
agtggcattg cttgtttctt aaaagaagat gacagttatt gggaccccaa tgacgaagag	300

11

agtatgaaca gccctgctg gcaagtcaag tggcaactcc gtcagctcgt tagaaagatg	360
atattgagaa cctctgagga aaccatttct acagttcaag aaaagcaaca aaatatttct	420
cccctagtga gagaaagagg tcctcagaga gtagcagctc acataactgg gaccagagga	480
agaagcaaca cattgtcttc tccaaactcc aagaatgaaa aggctctggg ccgcaaaata	540
aactcctggg aatcatcaag gagtgggcat tcattcctga gcaacttgca cttgaggaat	600
gggtgaactgg tcatccatga aaaagggttt tactacatct attcccaaac atactttcga	660
tttcaggagg aaataaaaaga aaacacaaag aacgacaaac aaatgggtcca atatatttac	720
aaatacacaa gttatcctga ccctatatgt ttgatgaaaa gtgctagaaa tagttgttgg	780
tctaaagatg cagaatatgg actctattcc atctatcaag ggggaatatt tgagcttaag	840
gaaaatgaca gaatttttgt ttctgtaaca aatgagcact tgatagacat ggaccatgaa	900
gccagttttt tcggggcctt tttagttggc taactgacct ggaaagaaaa agcaataacc	960
tcaaagtgac tattcagttt tcaggatgat acactatgaa gatgtttcaa aaaatctgac	1020
caaaacaaac aaacagaaaa cagaaaacaa aaaaacctct atgcaatctg agtagagcag	1080
ccacaaccaa aaaattctac aacacacact gttctgaaag tgactcactt atcccaagaa	1140
aatgaaattg ctgaaagatc tttcaggact ctacctata tcagtttgct agcagaaatc	1200
tagaagactg tcagcttcca aacattaatg caatgggttaa catcttctgt ctttataatc	1260
tactccttgt aaagactgta gaagaaagcg caacaatcca tctctcaagt agtgtatcac	1320
agtagtagcc tccaggtttc ctttaaggac aacatcctta agtcaaaaga gagaagaggc	1380
accactaaaa gatcgagtt tgcctggtgc agtggtcac acctgtaatc ccaacatttt	1440
gggaacccaa ggtgggtaga tcacgagatc aagagatcaa gaccatagtg accaacatag	1500
tgaaacccca tctctactga aagtgcacaaa attagctggg tgtgttggca catgcctgta	1560
gtcccagcta cttgagaggc tgaggcagga gaatcgtttg aacccgggag gcagagggtg	1620
cagtgtggtg agatcatgcc actacactcc agcctggcga cagagcgaga cttggtttca	1680
aaaaaaaaa aaaaaaaaaa cttcagtaag tacgtgttat ttttttcaat aaaattctat	1740
tacagtatgt caaaaaaaaaa aaaaaaaaaa	1769

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/027418 A3**

(51) International Patent Classification<sup>7</sup>: **G01N 33/48**

(21) International Application Number:  
PCT/EP2003/010404

(22) International Filing Date:  
18 September 2003 (18.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02021228.8 18 September 2002 (18.09.2002) EP

(71) Applicants (for all designated States except US):  
**G2M CANCER DRUGS AG** [DE/DE]; Paul-Ehrlich-  
Strasse 42-44, 60596 Frankfurt am Main (DE).  
**FORSCHUNGSZENTRUM KARLSRUHE GMBH**  
[DE/DE]; Hermann-von-Helmholtz-Platz 1, 76344 Eggen-  
stein-Leopoldshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HEINZEL,**  
**Thorsten** [DE/DE]; Libellenweg 10, 60529 Frankfurt am  
Main (DE). **KRÄMER, Oliver, H.** [DE/DE]; Koselstrasse  
38, 60318 Frankfurt am Main (DE). **GÖTTLICHER,**

Martin [DE/DE]; Marcesstrasse 1, 80638 München  
(DE). **ZHU, Ping** [CN/DE]; H.-Hesse-Strasse 13, 76351  
Linkenheim (DE). **GOLEBIEWSKI, Martin** [DE/DE];  
Bernhardstrasse 9, 76131 Karlsruhe (DE). **PELICCI,**  
**Pier, Giuseppe** [IT/IT]; Via Emilia 10, I-20090 Opera  
(Milan) (IT). **MAURER, Alexander, B.** [DE/DE]; Rain-  
weg 3, 61352 Bad Homburg (DE). **HENTSCH, Bernd**  
[DE/DE]; Gervinusstrasse 8, 60322 Frankfurt am Main  
(DE). **MINUCCI, Saverio** [IT/IT]; Via Don Minzoni 1,  
I-20090 Opera (Milan) (IT).


(74) Agents: **KELLER, Günter** et al.; **LEDERER &**  
**KELLER,** Prinzregentenstrasse 16, 80538 München (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: THE USE OF MOLECULAR MARKERS FOR THE PRECLINICAL AND CLINICAL PROFILING OF INHIBITORS OF ENZYMES HAVING HISTONE DEACETYLASE ACTIVITY



(57) Abstract: The present invention relates to the use of molecular markers and related signaling mechanisms for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of such markers as diagnostic and/or prognostic tools for the treatment of tumor patients with such inhibitors.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:  
13 May 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/10404

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 35990 A (JAMISON TIMOTHY F ; HARVARD COLLEGE (US); TAUNTON JACK (US); HASSIG) 2 October 1997 (1997-10-02) abstract; claims 50,63-73 ----	1-9, 19, 20
X	EP 1 050 581 A (MEDICAL & BIOLOG LAB CO LTD) 8 November 2000 (2000-11-08) abstract; claims 11,12,15 ----- -/-	1-9, 19, 20

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 March 2004

Date of mailing of the international search report

29/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

GONCALVES M L F C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/10404

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SU G H ET AL: "A NOVEL HISTONE DEACETYLASE INHIBITOR IDENTIFIED BY HIGH-THROUGHPUT TRANSCRIPTIONAL SCREENING OF A COMPOUND LIBRARY" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 12, 15 June 2000 (2000-06-15), pages 3137-3142, XP000985980 ISSN: 0008-5472 page 3137	1-9, 19, 20
<del>Y</del>	<del>KWON H-J ET AL: "A-histone deacetylase inhibitor, trichostatin A, induces apoptosis through suppression of anti-apoptotic factors, c-IAP-1 and c-IAP-2 in human prostate epithelial cells"</del> <del>PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US,</del> <del>vol. 40, March 1999 (1999-03), page 581</del> <del>XP002180771</del> <del>ISSN: 0197-016X</del> <del>abstract</del>	<del>1-9, 19, 20</del>
Y	SCHMIDT K ET AL: "INHIBITORS OF HISTONE DEACETYLASE SUPPRESS THE GROWTH OF MCF-7 BREAST CANCER CELLS" ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 332, no. 10, 1999, pages 353-357, XP000985303 ISSN: 0365-6233 page 354	1-9, 19, 20
Y	WARELL R P ET AL: "THERAPEUTIC TARGETING OF TRANSCRIPTION IN ACUTE PROMYELOCYTIC LEUKEMIA BY USE OF AN INHIBITOR OF HISTONE DEACETYLASE" JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDUCATION AND WELFARE, PUBLIC HEALTH, US, vol. 90, no. 21, November 1998 (1998-11), pages 1621-1625, XP002928827 ISSN: 0027-8874 abstract	1-9, 19, 20
A	JUNG M: "INHIBITORS OF HISTONE DEACETYLASE AS NEW ANTICANCER AGENTS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, 2001, pages 1505-1511, XP001098704 ISSN: 0929-8673 abstract	1-9, 19, 20
	-/-	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/10404

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>GREENBERG V L ET AL: "HISTONE DEACETYLASE INHIBITORS PROMOTE APOPTOSIS AND DIFFERENTIAL CELL CYCLE ARREST IN ANAPLASTIC THYROID CANCER CELLS" THYROID, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 11, no. 4, April 2001 (2001-04), pages 315-325, XP009003316 ISSN: 1050-7256 abstract</p>	1-9,19, 20
Y	<p>WO 00 71703 A (METHYLGENE INC) 30 November 2000 (2000-11-30) abstract; claims 28-39</p>	1-9,19, 20
X	<p>"SMALL MOLECULE INHIBITORS OF HISTONE DEACETYLASE" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 12, no. 6, 2002, pages 943-947, XP001120539 ISSN: 1354-3776 page 944 -page 945</p>	1-9,19, 20

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10-18

Present claims 10-17 relate to a product and the uses of a product defined by reference to a desirable characteristic or property, namely "means to determine the amount of a molecular marker". The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the methods of claims 1-9 and Kit of claims 19-20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10-18

Present claims 10-17 relate to a product and the uses of a product defined by reference to a desirable characteristic or property, namely "means to determine the amount of a molecular marker". The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the methods of claims 1-9 and Kit of claims 19-20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/10404

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 10-18  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/10404

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9735990	A	02-10-1997	AU	2990597 A	17-10-1997
			WO	9735990 A2	02-10-1997
EP 1050581	A	08-11-2000	EP	1050581 A1	08-11-2000
			WO	9936532 A1	22-07-1999
WO 0071703	A	30-11-2000	AU	6718200 A	12-12-2000
			CA	2366408 A1	30-11-2000
			EP	1173562 A2	23-01-2002
			WO	0071703 A2	30-11-2000
			JP	2003500052 T	07-01-2003
			US	2003078216 A1	24-04-2003

**THIS PAGE BLANK (USPTO)**